Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for InnoVira Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for InnoVira Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnoVira Therapeutics
Developer of small-molecule therapeutics designed to address viral-associated diseases. The company identifies molecular targets, designs antiviral compounds, validates candidates in preclinical studies, and advances them through clinical pathways, enabling healthcare providers, research institutions, and patients to access new treatment options that aim to reduce disease burden, improve outcomes, and expand interventions for conditions linked to viral infections.
- Sector
- Healthcare
- HQ
- Research Triangle Park, NC, United States
- Ownership
- Privately Held (backing)
InnoVira Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnoVira Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnoVira Therapeutics in its N-PORT filings yet. We sweep new filings monthly.